Updated:
Quanterix
Quanterix was founded in 2007 by David Walt, a Tufts University chemist, and spun out of his academic lab with an exclusive license to the single-molecule...
Quanterix
Quanterix was founded in 2007 by David Walt, a Tufts University chemist, and spun out of his academic lab with an exclusive license to the single-molecule array (Simoa) technology. Kevin Hrusovsky, a former PerkinElmer executive, joined as CEO in 2014 and took the company public on the Nasdaq in 2017. Walt’s work on fiber-optic microarrays forms the intellectual-property backbone — Quanterix instruments count individual enzyme-labeled protein molecules trapped in femtoliter-volume wells. The firm markets its Simoa HD-X and SR-X analyzers to pharmaceutical research teams running neurology, oncology, and immunology programs. Its core product is not a drug but a research-tool ecosystem — instruments, consumable kits, and contract services — that generates recurring revenue from assay sales. Confirmed users include Eli Lilly’s Alzheimer’s division, which relies on Simoa’s p-tau217 blood test to screen trial participants. Quanterix also operates an Accelerator Lab in Billerica that provides sample-testing services to biotechs without in-house Simoa capacity. Quanterix employs several hundred people, with its headquarters and laboratory footprint concentrated in Billerica, Massachusetts. It maintains no additional offices of record. In February 2024 the firm announced a strategic partnership with Johnson & Johnson’s Janssen unit to co-develop blood-based biomarker assays for Alzheimer’s disease diagnostics (per company press release, February 2024). The deal signals a shift from research-use-only toward clinical-diagnostic regulatory pathways. Quanterix occupies an unusual position: it is a public life-sciences tools company that behaves like a precision-diagnostics platform. Its intellectual-property moat rests on the Simoa patent estate and a growing library of multiplexed assay kits. The successor-product line under development, the Simoa One platform, aims to consolidate high-throughput and high-sensitivity workflows into a single instrument, which would let reference labs run both clinical trials and routine testing on one machine.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Billerica
Corporate office
Billerica, MA, United States
Principals
Kevin Hrusovsky
Chairman and Chief Executive Officer
Sector focus
Frequently asked questions
What does Quanterix actually sell?
Quanterix sells a hardware-and-reagents platform called Simoa (single-molecule array). The product line includes the HD-X analyzer for research labs and the SR-X for smaller studies, along with consumable assay kits for proteins like p-tau217, NfL, and IL-6. Roughly half of revenue comes from recurring consumable sales and service contracts, with the remainder from instrument placements (per the firm's public filings, 2023). In recent years it has added an Accelerator Lab service that runs client samples on Quanterix instruments for a fee.
Who are Quanterix's main customers?
Its customer base is concentrated in pharmaceutical R&D and academic research centers. Large biopharma clients use Simoa to measure blood-based biomarkers in clinical trials, particularly in Alzheimer’s disease. The firm has disclosed relationships with Eli Lilly, the National Institutes of Health, and various academic medical centers. In February 2024 it expanded into diagnostics through a partnership with Johnson & Johnson's Janssen unit.
How does the Simoa technology work?
Simoa works by isolating individual protein molecules in microscopic wells and using enzyme amplification to generate a detectable fluorescent signal from a single molecule. Conventional ELISA measures signal in bulk solution across the entire well; Simoa effectively digitizes the measurement so that each molecule is counted individually. The approach achieves femtomolar-level sensitivity, which is roughly a thousand times more sensitive than standard immunoassays (per peer-reviewed literature, 2010-2020).
Is Quanterix a diagnostics company or a research-tools company?
It has historically operated as a research-tools company, selling instruments and assays labeled for research-use-only. The February 2024 Janssen partnership, however, indicates a strategic move toward regulated clinical diagnostics. As of mid-2025 the company still generates the majority of its revenue from pharmaceutical research customers, but a clinical-diagnostics pipeline is now a stated corporate priority.
What is Quanterix's competitive moat?
Quanterix's primary defensibility comes from its patent estate on single-molecule array technology, licensed from Tufts University, and the accumulated know-how in manufacturing ultra-sensitive consumable assay kits. The installed base of roughly 1,200 instruments creates a recurring-revenue stream from assay sales. Competitors in the ultrasensitive immunoassay space include Singulex and Meso Scale Discovery, but neither offers the same combination of fully automated workflow and sub-femtomolar sensitivity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: